NYSE - Nasdaq Real Time Price USD

Eli Lilly and Company (LLY)

Compare
916.42 +3.10 (+0.34%)
At close: October 16 at 4:00 PM EDT
923.20 +6.78 (+0.74%)
Pre-Market: 8:53 AM EDT
Loading Chart for LLY
DELL
  • Previous Close 913.32
  • Open 910.03
  • Bid 916.00 x 1000
  • Ask 923.27 x 1000
  • Day's Range 897.84 - 917.80
  • 52 Week Range 547.61 - 972.53
  • Volume 1,275,363
  • Avg. Volume 3,121,164
  • Market Cap (intraday) 825.168B
  • Beta (5Y Monthly) 0.42
  • PE Ratio (TTM) 112.31
  • EPS (TTM) 8.16
  • Earnings Date Oct 30, 2024
  • Forward Dividend & Yield 5.20 (0.57%)
  • Ex-Dividend Date Aug 15, 2024
  • 1y Target Est 1,010.17

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

www.lilly.com

43,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: LLY

View More

Performance Overview: LLY

Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

LLY
57.98%
S&P 500
22.49%

1-Year Return

LLY
51.44%
S&P 500
35.00%

3-Year Return

LLY
297.57%
S&P 500
30.66%

5-Year Return

LLY
794.95%
S&P 500
95.03%

Compare To: LLY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LLY

View More

Valuation Measures

Annual
As of 10/16/2024
  • Market Cap

    822.38B

  • Enterprise Value

    847.90B

  • Trailing P/E

    112.86

  • Forward P/E

    40.82

  • PEG Ratio (5yr expected)

    0.87

  • Price/Sales (ttm)

    21.28

  • Price/Book (mrq)

    60.84

  • Enterprise Value/Revenue

    21.86

  • Enterprise Value/EBITDA

    75.76

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    18.86%

  • Return on Assets (ttm)

    13.70%

  • Return on Equity (ttm)

    59.25%

  • Revenue (ttm)

    38.92B

  • Net Income Avi to Common (ttm)

    7.34B

  • Diluted EPS (ttm)

    8.16

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.37B

  • Total Debt/Equity (mrq)

    212.88%

  • Levered Free Cash Flow (ttm)

    -675.32M

Research Analysis: LLY

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 11.3B
Earnings 2.97B
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

640.00 Low
1,010.17 Average
916.42 Current
1,158.00 High
 

Company Insights: LLY

Research Reports: LLY

View More
  • Eli Lilly's Cardiometabolic Portfolio and Pipeline Support Strong Growth and a Wide Moat

    Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

    Rating
    Price Target
     
  • Eli Lilly's Cardiometabolic Portfolio and Pipeline Support Strong Growth and a Wide Moat

    Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

    Rating
    Price Target
     
  • Eli Lilly's Cardiometabolic Portfolio and Pipeline Support Strong Growth and a Wide Moat

    Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

    Rating
    Price Target
     
  • Bond Spreads Widen a Bit

    Yields on Treasury bonds have been declining in recent weeks as concerns over inflation have eased. Meanwhile, corporate bond yields have declined as well, but not as rapidly as have Treasury yields -- this as fixed-income investors are now more concerned about a slowing economy and rising bond default rates. As a consequence, spreads between corporate and Treasury bond yields have widened in recent months. The spread between AAA-rated corporate bonds and 10-year government bonds in August was 110 basis points (bps), below the 35-year average of 122 bps but up 35 bps from April. The gap between the government 10-year bond yield and a BAA-rated bond (still investment grade) in August was 183 basis points, below the historical average spread of 229 bps and but up about 40 bps in the past three months. We watch these spreads closely for multiple reasons. From an asset-allocation standpoint, tight corporate bond spreads signal that corporate bond prices are above historical fair value, and we may look to underweight the segment in our model portfolios. From a broad-market standpoint, the changes in the spreads offer clues to the bond market's view of corporate financial strength (which currently appears to be improving given the narrowing spreads). This is important as the economy approaches a period of slower growth.

     

Top Analysts: LLY

View More

Overall Score

Cantor Fitzgerald 82/100
Latest Rating
Overweight
 

Direction Score

Cantor Fitzgerald 89/100
Latest Rating
Overweight
 

Price Score

Barclays 100/100
Latest Rating
Overweight
 

People Also Watch